A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma

Trial Profile

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs MORAB 028 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Morphotek
  • Most Recent Events

    • 15 Jul 2014 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top